<html>
<head>
  <title>SARS-CoV-2 Spike protein (S) gene H69del;V70del;Y144del;Y145del;N501Y;A570D;D614G;P681H literature reference collection</title>
  <link rel="stylesheet" href="constellations.css">
</head>
<body>
<h1><a href="front.html">SARS-CoV-2</a> <a href="S.html">Spike protein (S)</a> gene <span class="constellation">S:p.H69_V70del;Y144del;Y145del;N501Y;A570D;D614G;P681H</span> literature reference collection</h1>
<div class="effect_section"><h2 id="antibody_epitope_effects">Antibody epitope effects</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> B.1.1.7 variant constellation ablates Class 3 N-terminal domain targeting antibody COV2-2489. <br/> (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
</ul></div>
<div class="effect_section"><h2 id="vaccine_neutralization_efficacy">Vaccine neutralization efficacy</h2>
<ul class="lit_list">
<li class="lit_item"><span class="lit_summary"> The neutralizing activity of vaccine was somewhat lower against B.1.1.7 in sera tested from most of the 24 patients with the BNT162b2 mRNA vaccine. (Fig. 4) (<a href="https://doi.org/10.1038/s41591-021-01294-w" class="lit_link">Chen et al. (2021)</a>)</span></li>
</ul></div>
<div class="acknowledgement">Automatically generated using text2ui script and data from <a href="https://github.com/nodrogluap/pokay">Pokay</a></div>
</body>
</html>
